TransMedics Reports Second Quarter 2022 Financial Results
TransMedics Group reported a remarkable 151% increase in net revenue for Q2 2022, reaching $20.5 million compared to $8.2 million in Q2 2021. This growth is attributed to the use of the National OCS Program, which contributed 84% of total US revenue. The company has raised its 2022 revenue guidance to $67 million to $75 million, indicating an expected growth of 121% to 148% year-over-year. Additionally, TransMedics secured a $60 million non-dilutive debt financing to enhance financial flexibility.
- Net revenue increased by 151% to $20.5 million in Q2 2022.
- 2022 revenue guidance raised to $67 million to $75 million, reflecting 121% to 148% growth.
- Gross margin improved to 70% compared to 68% in Q2 2021.
- Secured a $60 million non-dilutive loan agreement to enhance financial flexibility.
- Net loss increased to $11.5 million in Q2 2022 from $10.7 million in Q2 2021.
- Operating expenses rose to $24.1 million, up from $15.5 million in Q2 2021.
Accelerated Commercial Momentum to Achieve Net Revenue of
2022 Revenue Guidance Range Raised to
ANDOVER, Mass., Aug. 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022. The Company also announced it entered into a new
Recent Highlights
- Net revenue of
$20.5 million in the second quarter of 2022, a151% increase compared to the second quarter of 2021. Transplant centers use of the National OCS Program (NOP) drove84% of total US revenue. - Integrated OCS™ Heart DCD offering into NOP
- Refinanced outstanding debt with new
$60 million term loan
"For the third sequential quarter we posted significant growth over the same period from the previous year. The second quarter results further validated that NOP is a critical catalyst that will fuel our expected growth for the foreseeable future," said Waleed Hassanein, MD, President, and Chief Executive Officer. "We are still very early on our growth trajectory, and we fully expect to continue to build on our momentum. We look forward to further broadening our NOP infrastructure and resources with the goal to maximize our coverage capacity and drive significant growth in transplant procedures in the US and around the world over the next several years."
"We are pleased to have secured a non-dilutive debt financing, enabling us to retire our existing debt facility while providing TransMedics with incremental financial flexibility to continue to scale the business," said Waleed Hassanein, MD, President, and Chief Executive Officer. "We look forward to a long-term and successful partnership with CIBC Innovation Bank as we continue grow our market presence."
Debt Financing Agreement
On July 25, 2022, TransMedics entered into a new
Cowen acted as exclusive financial advisor to TransMedics on this transaction. Additional detail regarding the financing is set forth in the Company's Current Report on Form 8-K, filed with the SEC.
Second Quarter 2022 Financial Results
Net revenue for the second quarter of 2022 was
Gross margin for the second quarter of 2022 was
Operating expenses for the second quarter of 2022 were
Net loss for the second quarter of 2022 was
Cash, cash equivalents and marketable securities were
2022 Financial Outlook
TransMedics is updating full year 2022 net revenue to be in the range of
Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Monday, August 1, 2022. Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, followed by Conference ID: 626851. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, our full year guidance, and statements about our operations, financial position, and business plans. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Some of the key factors that could cause actual results to differ include: that we continue to incur losses; our need to raise additional funding; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject to until maturity, and our ability to obtain additional financing or refinance existing debt on favorable terms or at all; the fluctuation of our financial results from quarter to quarter; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the OCS; our ability to expand access to OCS through the National OCS Program; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private payors of benefits offered by the OCS; our ability to improve the OCS platform; our dependence on a limited number of customers for a significant portion of our net revenue; our ability to maintain regulatory approvals or clearances for our OCS products, including the re-certification of the CE marks for our OCS products in the European Union and any delays in obtaining re-certification; our ability to adequately respond to FDA follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; price increases of the components of our products; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to attract and retain key personnel; the impact of the outbreak of COVID-19, including variants of the virus and associated containment, remediation and vaccination efforts; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products that are or may become available; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available by our annual and quarterly reports and other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
TransMedics Group, Inc. | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Net revenue | $ 20,521 | $ 8,171 | $ 36,401 | $ 15,224 | ||||
Cost of revenue | 6,171 | 2,582 | 9,947 | 4,824 | ||||
Gross profit | 14,350 | 5,589 | 26,454 | 10,400 | ||||
Gross Margin | 70 % | 68 % | 73 % | 68 % | ||||
Operating expenses: | ||||||||
Research, development and clinical trials | 6,714 | 6,295 | 14,248 | 10,827 | ||||
Selling, general and administrative | 17,381 | 9,162 | 31,320 | 15,948 | ||||
Total operating expenses | 24,095 | 15,457 | 45,568 | 26,775 | ||||
Loss from operations | (9,745) | (9,868) | (19,114) | (16,375) | ||||
Other income (expense): | ||||||||
Interest expense | (972) | (965) | (1,932) | (1,917) | ||||
Other income (expense), net | (784) | 171 | (1,011) | (283) | ||||
Total other expense, net | (1,756) | (794) | (2,943) | (2,200) | ||||
Loss before income taxes | (11,501) | (10,662) | (22,057) | (18,575) | ||||
Provision for income taxes | (22) | (6) | (28) | (10) | ||||
Net loss | $ (11,523) | $ (10,668) | $ (22,085) | $ (18,585) | ||||
Net loss per share attributable to common stockholders, | $ (0.41) | $ (0.39) | $ (0.79) | $ (0.68) | ||||
Weighted average common shares outstanding, basic and | 27,983,629 | 27,620,764 | 27,967,072 | 27,495,125 | ||||
* Reconciliation of Gross to Net revenue for certain payments made to customers (in thousands)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Gross revenue from sales to customers | $ 20,521 | $ 8,667 | $ 36,401 | $ 16,304 | ||||
Less: clinical trial payments reducing revenue | — | 496 | — | 1,080 | ||||
Total net revenue | $ 20,521 | $ 8,171 | $ 36,401 | $ 15,224 | ||||
TransMedics Group, Inc. | ||||
June 30, 2022 | December 31, 2021 | |||
Current assets: | ||||
Cash and cash equivalents | $ 30,386 | $ 25,580 | ||
Marketable securities | 27,697 | 66,872 | ||
Accounts receivable | 12,979 | 5,934 | ||
Inventory | 17,468 | 14,859 | ||
Prepaid expenses and other current assets | 6,583 | 5,460 | ||
Total current assets | 95,113 | 118,705 | ||
Property and equipment, net | 16,177 | 9,841 | ||
Operating lease right-of-use assets | 5,495 | 5,847 | ||
Restricted cash | 500 | 500 | ||
Total assets | $ 117,285 | $ 134,893 | ||
Current liabilities: | ||||
Accounts payable | $ 5,711 | $ 6,651 | ||
Accrued expenses and other current liabilities | 15,420 | 16,337 | ||
Deferred revenue | 238 | 250 | ||
Operating lease liabilities | 1,372 | — | ||
Total current liabilities | 22,741 | 23,238 | ||
Long-term debt, net of discount | 35,475 | 35,197 | ||
Operating lease liabilities, net of current portion | 8,150 | 8,604 | ||
Total liabilities | 66,366 | 67,039 | ||
Total stockholders' equity | 50,919 | 67,854 | ||
Total liabilities and stockholders' equity | $ 117,285 | $ 134,893 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2022-financial-results-301597142.html
SOURCE TransMedics Group, Inc.
FAQ
What were TransMedics' Q2 2022 revenue results?
What is TransMedics' updated 2022 revenue guidance?
What major financial moves did TransMedics make recently?
How did operating expenses change for TransMedics in Q2 2022?
What was the gross margin for TransMedics in Q2 2022?
